Attached files
| file | filename |
|---|---|
| S-1MEF - S-1MEF - Edgewise Therapeutics, Inc. | tm2037601d19_s1mef.htm |
| EX-5.1 - EXHIBIT 5.1 - Edgewise Therapeutics, Inc. | tm2037601d19_ex5-1.htm |
Exhibit 23.1
Consent of Independent Registered Public Accounting Firm
The Board of Directors
Edgewise Therapeutics, Inc.:
We consent to the use of our report dated March 1, 2021, except as to the reverse stock split information in note 10, which is as of March 19, 2021, incorporated by reference herein, and to the reference to our firm under the heading “Experts” in the prospectus.
/s/ KPMG LLP
Denver, Colorado
March 25, 2021